ACADIA Pharmaceuticals Inc. (ACAD) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| GAAP Research and Development Expenses | 77M | FY2026-Q1 |
| GAAP Selling, General and Administrative Expenses | 171M | FY2026-Q1 |
| Net Product Sales of DAYBUE | 101M | FY2026-Q1 |
| Net Product Sales of NUPLAZID | 167M | FY2026-Q1 |
Back to ACAD overview · ACAD earnings · ACAD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.